Vaxcyte, Inc. Common Stock
PCVXVaxcyte, Inc. is a biotechnology company focused on developing next-generation vaccines aimed at preventing infectious diseases. Leveraging its proprietary conjugation platform, Vaxcyte develops innovative vaccines primarily targeting pneumococcal disease, with the goal of providing broader coverage and improved immune responses compared to existing options.
Company News
Pfizer reported positive Phase 2 data for its 25-valent pneumococcal conjugate vaccine candidate (25vPnC), showing 8.8 to 15 times higher immune responses against serotype 3 compared to PREVNAR 20. The company is advancing to a pivotal Phase 3 pediatric program with up to 2,400 participants and plans to develop a 35-valent adult vaccine candidate...
Vaxcyte announced publication of positive Phase 1/2 clinical trial results for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in The Lancet Infectious Diseases. The vaccine demonstrated robust immune responses across all 31 serotypes and a safety profile similar to Prevnar 20. Based on these results, VAX-31 has advanced into Phase ...
Vaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of common stock at $50 per share, including the full exercise of underwriters' option for 1,650,000 additional shares. The funds will support the company's clinical-stage va...
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, announced the pricing of an underwritten public offering of 11 million shares at $50 per share, generating $550 million in gross proceeds. The offering is expected to close on February 2, 2026. The company is developing VAX-31, a 31-valent pneumococcal conjugate vaccine candidate in ...
Vaxcyte announced progress on VAX-31, its 31-valent pneumococcal conjugate vaccine, with first participants dosed in the OPUS-2 Phase 3 adult trial evaluating concomitant administration with seasonal influenza vaccine. The company plans to initiate OPUS-3 Phase 3 trial in Q1 2026 for previously vaccinated adults and expects topline data from OPUS...
